The progressive ankylosis gene (ank) encodes a transmembrane protein that transports intracellular inorganic pyrophosphate (PP i ) to the extracellular milieu. ank/ank mice, which express a truncated nonfunctional ANK, showed a markedly reduced bone mass, bone-formation rate, and number of tartrate-resistant acid phosphatase-positive (TRAP þ ) multinucleated osteoclasts. ANK function deficiency suppressed osteoblastic differentiation of ank/ank bone marrow stromal cells, as indicated by the decrease in the expression of bone marker genes, including osterix, reduced alkaline phosphatase activity, and mineralization. Runx2 gene expression levels were not altered. Conversely, overexpression of ANK in the preosteoblastic cell line MC3T3-E1 resulted in increased expression of bone marker genes, including osterix. Whereas runx2 expression was not altered in ANK-overexpressing MC3T3-E1 cells, runx2 transcriptional activity was increased. Extracellular PP i or P i stimulated osteoblastogenic differentiation of MC3T3-E1 cells or partially rescued delayed osteoblastogenic differentiation of ank/ank bone marrow stromal cells. A loss of PP i transport function ANK mutation also stimulated osteoblastogenic differentiation of MC3T3-E1 cells. Furthermore, ANK function deficiency suppressed the formation of multinucleated osteoclasts from ank/ ank bone marrow cells cultured in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor-kB ligand.
Introduction

B
one is a dynamic organ that undergoes continuous remodeling, in which bone resorption by osteoclasts precedes bone formation by osteoblasts. A proper balance between bone resorption and bone formation is required to maintain bone mass and integrity. Impaired bone formation, resorption, or both results in either decreased bone mass, as observed in osteoporosis, or increased bone mass, as observed in osteopetrosis and osteosclerosis. (1, 2) Osteoblasts arise from mesenchymal stem cells that can differentiate into adipocytes, chondrocytes, myoblasts, and osteoblasts. The differentiation of multipotential mesenchymal stem cells into osteoblasts is controlled by two transcription factors, runx2 and osterix. Both runx2-and osterix-null mice show a complete absence of endochondral and intramembranous bone formation owing to a lack of osteoblast differentiation. (3) (4) (5) (6) Osterix has been shown to act downstream of runx2, and it has been suggested that runx2 regulates early differentiation of mesenchymal cells into preosteoblastic cells, whereas osterix controls the differentiation of preosteoblastic cells into immature osteoblasts. (6, 7) In addition, it has been suggested that runx2 regulates osterix expression. (8) Bone resorption involves both dissolution of bone mineral and degradation of the organic bone matrix. Both functions are performed by osteoclasts. Osteoclasts are members of the monocyte/macrophage lineage and are formed by multiple instances of cellular fusion of their mononuclear precursors. Monocytes can be induced to differentiate into osteoclasts in the presence of receptor activator of nuclear factor-kB (RANK) ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). RANKL and M-CSF are expressed by osteoblasts. Osteoclast precursor cells express RANK, which is the receptor for RANKL.
binding to RANK. RANKL/RANK signaling activates four pathways that mediate osteoclast formation [nuclear factor-kB (NF-kB), c-fos, and calcineurin/NFATc1] and three pathways that mediate osteoclast activation (Src and MKK6/p38/MITF) and survival (Src and extracellular signal-regulated kinase). (9) The progressive ankylosis gene (ank) encodes a transmembrane protein that transports intracellular inorganic pyrophosphate (PP i ) to the extracellular milieu. (12) Recently, human mutations in ank have been discovered that lead to craniometaphyseal dysplasia (CMD). (13, 14) CMD mutations have been identified in the human ank gene in the form of point mutations and one-amino-acid insertions or deletions that cluster mostly in cytoplasmic domains close to the C-terminus. The main phenotypes of the disease are progressive thickening of craniofacial bones and flaring metaphyses with increased radiolucency of long bones. (15) In addition, histopathologic studies of CMD patients showed either increased osteoblast numbers, no osteoclasts in periosteal or endosteal layers, or increased osteoblast and osteoclast numbers. (16) (17) (18) (19) Furthermore, a knock-in mouse model for CMD expressing a human mutation (Phe377 deletion) in ANK shows defects in bone formation and bone remodeling. (20) Altogether these findings suggest that ANK plays a regulatory role in bone formation and resorption and may directly affect osteoblast and osteoclast differentiation and/or function. Nevertheless, the exact role of ANK in these processes is not understood. A spontaneous mutation in the murine ank gene resulted in a premature stop codon and the expression of a nonfunctional protein. The lack of ANK function in these ank/ank mice caused generalized arthritis associated with extensive hydroxyapatite deposition in articular cartilage and synovial fluid. The presence of ectopic joint mineral formation in these mice eventually leads to complete fusion and immobility of almost every joint. In addition, these mice exert spinal, peripheral joint, and ligament bony ankylosis and calcification of arteries. (12) A homozygous
ank-null mouse model shows the same phenotype. (21) The ANK function-deficient ank/ank mice were used in this study to gain insights into the role of ANK in osteoblast and osteoclast differentiation and function. Here we report that ANK function deficiency suppressed bone formation as well as bone resorption by directly affecting osteoblast and osteoclast differentiation. Consequently, ANK function deficiency resulted in reduced numbers of mature osteoblasts and osteoclasts. These findings suggest that ANK is a novel regulator of bone remodeling.
Materials and Methods
Bone histomorphometry and micro-computed tomographic (mCT) analysis
The ank/ank breeding colony used was originally on a hybrid background derived from crossing a C3H and C57BL/6 hybrid male with a BALB/c female. Heterozygote breeders were used to generate and study ank/ank and wild-type littermates, with genotypes analyzed by polymerase chain reaction (PCR), as described previously. (12) ) multinucleated cells were counted as osteoclasts to evaluate osteoclast number/bone surface and osteoclast surface/bone surface. For dynamic bone histomorphometry, tetracycline hydrochloride (25 mg/kg) injection was followed by the same dose of calcein 7 days later, and animals were euthanized 2 days after that. Histomorphometric analysis of undecalcified sections of the proximal tibial metaphysis was performed by transmitted and epifluorescent microscopy using a microscope (Olympus IX71, Olympus America Inc., Center Valley, PA, USA) and OsteoMeasure analyzing software. Single-labeled (sLS/BS) and double-labeled (dLS/BS) surface, mineralizing surface (MS; dLS þ sLS/2)/BS), interlabel thickness (Ir.L.Th), and mineral apposition rate (Ir.L.Th/ Ir.L.t ¼ MAR) were measured and calculated. The interlabel time (Ir.L.t.) was 7 days. Bone-formation rate with bone surface as the referent (BFR/BS) was calculated as MAR Â MS (mm 3 /mm 2 /day).
Femurs and tibias from 4-week-old male ank/ank (n ¼ 5) and male wild-type littermates (n ¼ 5) were analyzed using mCT (Numira Biosciences, Salt Lake City, UT, USA). Trabecular measurements of femurs and tibias were taken at the distal growth plate in 80 consecutive slices of 12-mm resolution over a distance of 960 mm. The mCT bone analysis was performed by Numira Biosciences.
Mouse bone marrow stromal cell culture
Bone marrow stromal cells (BMSCs) were isolated from femurs of 4-week-old ank/ank mice or wild-type littermates and cultured at 2 Â 10 6 cells per 10-cm 2 well in a-minimal essential medium (a-MEM) supplemented with 15% fetal calf serum, as described previously. (24, 25) After cells reached confluence, they were cultured in the presence of 5 mM b-glycerophosphate, 50 mg/ mL of ascorbate, and 10 À7 M dexamethasone to induce osteoblastogenic differentiation for up to 16 days, as described previously. (24, 25) 
Real-time PCR analysis
Total RNA was isolated from cell cultures using the RNeasy Minikit (Qiagen, Valencia, CA, USA). Gene expression was quantified by real-time PCR analysis, as described previously. (28) Briefly, 1 mg of total RNA was reverse-transcribed using the Omniscript RT kit (Qiagen). A 1:100 dilution of the resulting cDNA was used as a template to quantify the relative content of mRNA by real-time PCR using SYBR Green. The 18S rRNA was amplified at the same time and used as an internal control. The cycle threshold values for 18S rRNA and the samples were measured and calculated by computer software. Relative transcription levels were calculated as Intracellular PP i measurements Intracellular PP i was measured with a spectrophotometric method using PP i -dependent fructose-6-phosphate kinase activity coupled with the disappearance of NADH (pyrophosphate reagent, Sigma). Cell layers were extracted with 0.5 mL of 1 M perchloric acid for 2 hours on ice and neutralized with 0.5 mL of 1 M KOH, and samples were centrifuged to remove the precipitate. Next, 0.4 mL of sample was added to 0.8 mL of reconstituted PP i reagent (Sigma) and incubated for 10 minutes at 308C. The absorption was measured at 340 nm. PP i concentrations were determined according to the manufacturer's instructions.
Statistical analysis
Numerical data are presented as mean AE SD (n ! 3). Statistical analysis was performed by Student's t test to evaluate differences between the two groups. Analysis of variance was performed when the examined experimental groups exceeded three. Tukey's multiple-comparison test was applied as a post hoc test. Statistical significance was defined as p < .05 ( p values are reported in the figure legends).
Results
Low bone mass, reduced bone-formation rate, and reduced number of osteoclasts in tibias and femurs of ank/ank mice Histomorphometric analysis of long bones of ank/ank mice and wild-type littermates revealed a low-bone-mass phenotype in 2-and 4-month-old ank/ank mice. Trabecular bone volume in the proximal tibial metaphysis was reduced by more than 40% in 2-month-old ank/ank mice and more than 50% in 4-month-old ank/ank mice relative to wild-type littermates (Fig. 1A, B) . This decreased bone volume was associated with a decrease in trabecular number and thickness and a significant increase in the mean distance between individual trabeculae ( Fig. 1C-E) . Dynamic histomorphometry showed abundant double tetracycline and calcein labels on the endocortical surface of wildtype mouse tibias. In contrast, primarily single labeling and few areas of double labels with reduced distance between the tetracycline and calcein labels were observed in ank/ank mice. Accordingly, parameters of new bone formation (MAR and BFR) were significantly higher in wild-type than in ank/ank mice ( Fig. 1F-H ).
To further characterize the bone phenotype of ank/ank mice, we analyzed the femurs and tibias of 4-week-old ank/ank and (Figs. 2A, C) . In addition, trabecular thickness was reduced in the femurs and tibias of 4-week-old ank/ank mice, whereas trabecular separation was increased in ank/ank femurs and tibias (Fig. 2C) . Trabecular numbers in 4-week-old ank/ank femurs and tibias were similar to those in wildtype femurs and tibias (Fig. 2C) . There was no difference between the cortical thickness of ank/ank and wild-type femurs and tibias (Figs. 2B, D) . Decreased numbers of TRAP þ cells were detected in the metaphysis of ank/ank femurs and tibias compared with wild-type littermates (Fig. 2E) . Quantitative analysis revealed a marked reduction in the number and surface area of TRAP þ osteoclasts in ank/ank femurs and tibias, suggesting that bone resorption was also reduced in ank/ank mice (Fig. 2E ).
Impaired osteoblastogenic differentiation and mineralization of bone marrow stromal cells (BMSCs) and calvarial osteoblasts isolated from ank/ank mice We isolated BMSCs from ank/ank mice and wild-type littermates and compared their ability to differentiate into mature mineralizing osteoblasts. Freshly isolated BMSCs were cultured in the presence of b-glycerophosphate, ascorbate, and ANK AND SKELETAL CELL DIFFERENTIATION dexamethasone to induce osteoblastogenic differentiation in these cells, as described previously. (24) ank mRNA levels were the lowest on day 0 of wild-type BMSC cultures in osteoblastogenic differentiation medium. ank mRNA levels increased in wild-type BMSCs when cultured in osteoblastogenic differentiation medium and reached their highest levels on day 4 (Fig. 3A) . APase mRNA levels, an early marker of osteoblastic differentiation, increased on day 4 and reached the highest levels between days 4 and 8. APase mRNA levels declined with the onset and progression of mineralization (Fig. 3B) . mRNA levels of osteocalcin, which is a late marker of osteoblast differentiation and increases during the onset of mineralization, were low up to day 8 in wild-type BMSC cultures and increased thereafter, reaching the highest level on day 12 (Fig. 3A) . After 6 days, cultures were stained for APase activity. The number of APasepositive colonies in ank/ank BMSCs was markedly reduced compared with those of APase-positive colonies in wild-type BMSCs (Fig. 3B) . Von Kossa staining after 16 days of culture was used to determine mineralized colonies in these cultures. The number of von Kossa þ colonies was markedly reduced in cultures of BMSCs isolated from ank/ank mice compared with those from wild-type mice (Fig. 3B ). Real-time PCR analysis revealed that the mRNA levels of bone marker genes, including APase, bone sialo protein (BSP), osteocalcin, and type I collagen, were reduced in ank/ank BMSCs that had been cultured for 10 days in osteoblastogenic differentiation medium compared with the mRNA levels of these genes in wild-type BMSCs (Fig. 4A) . The mRNA level of osterix also was markedly downregulated in ank/ank BMSCs, whereas the mRNA level of runx2 in ank/ank BMSCs was similar to that in wild-type BMSCs (Fig. 4A) . Furthermore, mRNA levels for bone marker genes, including APase, BSP, osteocalcin, osterix, runx2, and type I collagen, were decreased in ank/ank calvarial osteoblasts compared with the levels in wild-type calvarial osteoblasts (Fig. 4B) . mRNA levels of RANKL and OPG also were decreased in ank/ank calvarial osteoblasts compared with the levels in wild-type cells; however, the RANKL/OPG ratio was similar in ank/ank and wild-type calvarial osteoblasts (Fig. 4C) . Primary ank/ank calvarial osteoblasts demonstrated decreased matrix mineralization during the onset and early propagation phase of mineralization compared with the mineralization levels of wild-type cells, whereas at later stages of mineralization ank/ank calvarial osteoblasts showed increased mineralization (Fig. 4D) . These findings suggest that osteoblastogenic differentiation is delayed in ank/ank BMSCs and calvarial osteoblasts. However, once mineralization is initiated, ank/ank calvarial osteoblast matrix mineralization is increased because of the lack of extracellular PP i to inhibit extracellular matrix mineralization.
Overexpression of ANK or CMD mutant ANK (F376del) enhances osteoblastogenic differentiation and runx2 transcriptional activity
We first overexpressed wild-type ANK and the F376del CMD mutant ANK in COS cells, which do not normally express ANK. The F376del mutant ANK completely lost its ability to transport intracellular PP i , as indicated by the same intracellular PP i concentration in COS cells transfected with empty vector or vector containing F376del mutant ank cDNA (Fig. 5A) . In contrast, COS cells transfected with vector containing wild-type ank cDNA showed a reduced intracellular PP i concentration (Fig. 5A) . Next, we overexpressed wild-type and F376del mutant ANK in the preosteoblastic cell line MC3T3-E1. Cells transfected with expression plasmids encoding wild-type or F376del mutant ank showed markedly increased ANK protein expression compared with the levels in cells transfected with empty vector (Fig. 5B) . Overexpression of wild-type ANK in MC3T3-E1 cells resulted in increased osteoblastogenic differentiation, as indicated by the increased mRNA kevels of bone marker genes, including APase, BSP, osteocalcin, and type I collagen (Fig. 5C ). In addition, osterix expression was markedly upregulated in ANKoverexpressing MC3T3-E1 cells, whereas runx2 expression was elevated only slightly (Fig. 5D) . Overexpression of the F376del mutant form of ANK also resulted in increased mRNA levels of these bone marker genes despite the loss of PP i transport activity of the F376del mutant ANK (Fig. 5C, D) . Contrary to the overexpression of wild-type ANK, overexpression of the F376del mutant ANK resulted in increased mRNA levels of runx2 (Fig. 5D ). MC3T3-E1 cells cotransfected with wild-type ANK expression plasmid and the luciferase reporter construct pOSE2 (containing six runx2 DNA-binding elements) showed increased luciferase activity compared with cells cotransfected with empty vector and the pOSE2 luciferase reporter construct (Fig. 5E ). Cotransfection of cells with the expression plasmid encoding F376del mutant ank and the pOES2 luciferase reporter construct resulted in a further increase in luciferase activity compared with the activity of wild-type ANK-overexpressing cells (Fig. 5E ).
Since wild-type ANK regulates extracellular PP i /P i homeostasis, we determined whether extracellular PP i regulates osteoblast differentiation and mineralization. We cultured MC3T3-E1 cells in osteoblastogenic differentiation medium in the absence or presence of 0.5 mM PP i for the first 6 days of a 12-day culture period. In the presence of PP i , mRNA levels of BSP, osteocalcin, osterix, and type I collagen were increased, whereas mRNA levels of APase and runx2 were unchanged or slightly increased (Fig. 6A) . To determine whether the alterations in bone marker gene expression were directly attributable to PP i and not its hydrolysis product P i , we treated MC3T3-E1 cells with a specific APase inhibitor, levamisole. Levamisole treatment alone resulted in increases in BSP and osterix mRNA levels and a slight increase of osteocalcin mRNA levels, whereas the mRNA levels of the other bone marker genes were slightly decreased compared with untreated cells (Fig. 6A) . Levamisole/PP i treatment showed the same regulatory patterns of bone marker gene mRNA levels as levamisole treatment, with levamisole/PP i treatment being more effective in altering the mRNA levels of these markers (Fig. 6A) . To determine the effect of extracellular PP i and/or P i on mineralization, we cultured MC3T3-E1 cells for the first 6 days or the last 6 days of a 12-day culture period with PP i , levamisole, or levamisole and PP i and determined the degree of mineralization by alizarin red S staining after the 12-day culture period. PP i and levamisole/PP i treatment during the first 6 days of the 12-day culture period enhanced the degree of mineralization of MC3T3-E1 cells, whereas levamisole alone did not change the degree of The levels of bone marker mRNAs, including APase, BSP, osteocalcin (OC), osterix, runx2, and type I collagen (Col1A1), of wild-type and ank/ank BMSCs cultured for 10 days in osteoblastogenic differentiation medium (A) and wild-type and ank/ank calvarial osteoblasts (B) and the mRNA levels of RANKL and OPG of wild-type and ank/ank calvarial osteoblasts (C) were determined by real-time PCR and SYBR Green and normalized to 18S RNA levels. Data were obtained from triplicate PCRs using RNA from three different cultures, and values are presented as means AE SD ( a p < .01 versus WT; b p < .
versus WT). (D)
The degree of mineralization in wild-type and ank/ank calvarial osteoblasts was determined using alizarin red S staining. To quantitate the alizarin red S stain, each dish was incubated with cetylpyridinium chloride for 1 hour. The optical density of alizarin red S stain released into solution was measured at 570 nm, normalized to total amount of protein, and expressed as relative units compared with the optical density per milligram of protein of WT cells after a 10-day culture period, which was set as 1. Data were obtained from four different experiments, and values are presented as means AE SD ( a p < .01 versus mineralization (Fig. 6B) . PP i treatment during the last 6 days of the 12-day culture period enhanced mineralization of MC3T3-E1 cells, whereas levamisole or levamisole/PP i treatment did not alter the degree of mineralization compared with the mineralization of untreated MC3T3-E1 cells (Fig. 6C ). These findings suggest that PP i directly and P i resulting from the hydrolysis of PP i stimulate osteoblastogenic differentiation and as a consequence mineralization. In addition, P i propagates mineral formation, whereas PP i inhibits the propagation of mineralization. Since extracellular P i seemed to be more effective in stimulating osteoblastogenic differentiation and mineralization, we determined whether extracellular P i can rescue the delayed osteoblastogenic differentiation of ank/ank BMSCs. ank/ank and wild-type BMSCs were cultured in osteoblastogenic differentiation medium that contains 1 mM P i in the absence or presence of additional 1.5 mM extracellular P i for 10 days. The additional 1.5 mM P i increased the mRNA levels of APase, BSP, osteocalcin, osterix, and type I collagen of ank/ank BMSCs to levels similar to or higher than those of untreated wild-type cells (Fig. 6D) . And 1.5 mM P i treatment of wild-type BMSCs resulted in further increases of APase, BSP, osteocalcin, runx2, and type I collagen mRNA levels. But 1.5 mM P i did not affect the mRNA levels of osterix in wild-type BMSCs or runx2 mRNA levels in ank/ank BMSCs (Fig. 6D) .
ANK is expressed in osteoclast precursor cells and affects osteoclast differentiation
Our observation that ANK function-deficient mice exhibited an osteoclastic phenotype (Fig. 2E ) prompted us to determine the role of ANK in osteoclastogenesis. When bone marrow cells isolated from wild-type mice were induced to undergo osteoclastic differentiation in vitro by the addition of RANKL and M-CSF, ANK expression was the highest during the initial phase of osteoclast differentiation and decreased in the later stages of osteoclast differentiation (Fig. 7A) . After 6 days of treatment with RANKL and M-CSF, most wild-type bone marrow cells differentiated into mature osteoclasts (Fig. 7B) . Osteoclastogenesis in cultures of ank/ank bone marrow cells in the presence of M-CSF and RANKL for 6 days was suppressed, as indicated by the reduced number of TRAP þ multinucleated cells in these cultures compared with wild-type bone marrow cell cultures (Fig. 7B, C) . Because osteoclastogenesis is under the control of RANKL/RANK signaling, we analyzed the expression levels of the genes downstream of this axis. The expression level of c-fos was decreased in ank/ank bone marrow cell cultures treated with M-CSF and RANKL. NFATc1 expression level, which is a target of c-fos, also was decreased in ank/ank bone marrow cell cultures compared with wild-type cells (Fig. 7D ). In addition, RANK and TRAP mRNA levels were markedly reduced in ank/ank bone marrow cell cultures compared with wild-type bone marrow cell cultures (Fig. 7D) . (B, C) MC3T3-E1 cells were cultured for a total of 12 days. The cells were either treated for the first 6 days (B) or the last 6 days (C) with 0.5 mM PP i and/or levamisole. Mineralization was determined by alizarin red S staining. Alizarin red S stain was quantitated as described in Fig. 4 and is expressed as relative units compared with the optical density per milligram of protein of untreated cells, which was set as 1. Data were obtained from four different experiments, and values are presented as means AE SD ( a p < .01 versus untreated cells). (D) ank/ank and wild-type (WT) BMSCs were cultured in medium containing ascorbate and 1 or 2.5 mM P i for 10 days. mRNA levels of APase, BSP, osteocalcin (OC), osterix, runx2, and type I collagen (Col1A1) were determined by realtime PCR and SYBR Green and normalized to 18S RNA levels. Data were obtained from triplicate PCRs using RNA from three different cultures, and values are presented as means AE SD ( a p < .01 versus wild-type BMSCs cultured in the presence of 1 mM P i ; b p < .01 versus ank/ank BMSCs cultured in the presence of 1 mM P i ).
Discussion
Our findings demonstrate that ANK, a transmembrane protein that transports intracellular PP i to the extracellular milieu regulates both aspects of bone remodeling: bone formation and bone resorption. Loss of ANK function resulted in delayed osteoblastogenic differentiation of BMSCs, as reflected by reduced numbers of APase þ and von Kossa þ colonies and reduced expression of bone marker genes, including APase, BSP, osteocalcin, and type I collagen. In addition, osterix expression was decreased in ank/ank BMSCs cultured in osteoblastogenic differentiation medium, whereas runx2 expression was not altered. Conversely, overexpression of ANK resulted in increased osteoblastogenic differentiation of the preosteoblastic cell line MC3T3-E1 and increased osterix expression, whereas runx2 expression was not affected. Overexpression of ANK, however, resulted in stimulation of runx2 transcriptional activity. ank/ank calvarial osteoblasts also showed decreased expression of bone marker genes, including osterix and runx2. Consequently, the degree of mineralization was decreased during the initiation and early propagation of mineralization of these cells. However, at later stages, mineralization was increased in calvarial osteoblasts lacking ANK function, consistent with the notion that extracellular PP i acts as an inhibitor of mineralization via binding to newly formed mineral crystals and preventing their growth. (29) These findings suggest that ANK regulates osteoblast differentiation and mineralization at different levels; ANK is required for osteoblastogenic differentiation into mature osteoblasts, and ANK controls the propagation of osteoblast extracellular matrix mineralization. The extensive hydroxyapatite deposition in articular cartilage and synovial fluid; the spinal, peripheral joint, and ligament bony ankylosis; and the calcification of arteries were attributed to the lack of extracellular PP i to inhibit mineral formation in these tissues of ank/ank and ank-null mice. (12, 15) This notion is supported by the findings that nucleotide pyrophosphatase phosphodiesterase 1 (NPP1)-deficient mice show a similar joint phenotype as ank/ank mice, and these mice also show arterial calcification. (30, 31) NPP1 is an enzyme located on the outer plasma membrane that generates extracellular PP i by the hydrolysis of ATP. (32) Our results show that extracellular PP i directly regulates the expression of osteoblast marker genes, including APase, BSP, and osterix. In addition, treatment of nonmineralized osteoblastic cells with PP i even in the presence of the APase-specific inhibitor levamisole resulted in increased mineralization, suggesting that PP i directly regulates osteoblastogenic differentiation. In contrast, treatment of osteoblastic cells with PP i in the presence of levamisole beginning shortly before the initiation of mineralization inhibited the mineralization process because of the inhibitory role of PP i in mineral crystal formation and growth. Therefore, extracellular PP i stimulates osteoblastogenic differentiation and, as a result, stimulates the initiation and early propagation of mineralization. Furthermore, extracellular PP i controls the propagation and degree of mineralization by regulating mineral crystal growth. Our findings are consistent with a recent finding showing that extracellular PP i not only inhibited mineral crystal growth but also directly and independent of its hydrolysis to P i regulated osteopontin expression in osteoblasts. (29) Even though no receptor or transport system for extracellular PP i is known, the possibility that PP i acts through a transmembrane receptor is not unreasonable. Other small molecules also signal through receptors in osteoblasts, including the calcium-sensing receptor, (33) the nucleotide P2-purine receptor, (34) and the bisphosphonates (PP i analogues) acting through connexin 43 hemichannels. (35) In addition, our findings show that extracellular P i resulting from the hydrolysis of PP i regulates osteoblastogenic differentiation. Extracellular P i treatment of ank/ank BMSCs resulted in increases in mRNA levels of bone marker genes, including APase, BSP, osteocalcin, osterix, and type I collagen. In addition, P i further increased the mRNA levels of these bone marker genes and runx2 in wild-type BMSCs. Previous studies demonstrated that P i affects cellular differentiation and function of a variety of cells, including chondrocytes, osteoblasts, osteoclasts, and vascular smooth muscle cells. (36) (37) (38) (39) The primary mechanism for P i entry through the cell membrane is via a family of Na þ -dependent P i transporters. (40, 41) Taken together, our findings suggest that ANK-mediated control of osteoblastogenic differentiation and mineralization is mediated by extracellular PP i /P i homeostasis and that the lack of ANK function to regulate this homeostasis results in delayed osteoblastogenic differentiation.
Our findings reveal that ANK also acts as an intrinsic regulator of osteoclast differentiation. The number and surface area of osteoclasts were markedly reduced in ank/ank mice. In addition, ank/ank precursor cells, when cultured in the presence of RANKL and M-CSF, showed a markedly reduced number of mature osteoclasts after 6-day culture. Our findings also reveal that ank/ank osteoblasts show lower RANKL and OPG mRNA levels than wild-type osteoblasts; however, the RANKL/OPG ratio was the same. Therefore, it is possible that mature osteoclast numbers are reduced in ank/ank mice owing to (1) the loss of ANK function in osteoclast precursors resulting in inhibition of osteoclast differentiation and (2) the reduced levels of RANKL in ank/ank osteoblasts resulting in a less effective support of osteoclastogenesis than by wild-type BMSCs and osteoblasts.
Bone formation and bone resorption are two arms of a tightly coupled remodeling process. Imbalance between these two processes can lead to either increased bone mass (osteopetrosis) or decreased bone mass (osteopenia, osteoporosis). Our data indicate that ANK affects both osteoblast and osteoclast differentiation, with the net outcome of reduced bone mass. There are few other examples of a single protein suppressing the differentiation and/or function of both cell types. (42) (43) (44) In all cases where a single protein delayed both bone formation and bone resorption, the net outcome was decreased bone mass. (42) (43) (44) This outcome was explained by the fact that bone formation is notably slower than bone resorption. The different phenotypes in cranium (hyperostosis) and long bones (osteopenia) in ank/ank mice may result from the different rates of bone remodeling or turnover in craniofacial and long bones. Bone turnover in long bones is much higher than in calvarial bones. (45) Suppression of osteoblast differentiation leads to the formation of immature woven bone, which is easily being resorbed. Therefore, it is possible that the long bone formed in mice lacking ANK function is immature and easily resorbed, resulting in the osteopenic phenotype of the long bones, whereas turnover of craniofacial bone is much lower, eventually resulting in maturation of the immature woven bone and hyperostosis because of the reduced number of functional osteoclasts in ank/ank mice. CMD patients and a CMD mouse model show similar but milder phenotypes as ank/ank and anknull mice, including hyperostosis of the cranium and osteopenia of the long bones. Our findings revealed that the F376del CMD mutation of ANK stimulated osteoblastogenic differentiation to an even higher degree than wild-type ANK. These findings are consistent with previous studies showing elevated serum APase and TRAP levels in CMD patients and a CMD mouse model, suggesting increased bone formation and bone resorption resulting in increased bone turnover in CMD patients. (13, 16, 31) The increased bone turnover in long bones explains the osteopenic phenotype in CMD patients and the CMD mouse model, whereas the hyperostosis of the cranium results from the low bone turnover and increased bone formation. Therefore, the similar phenotype of ank/ank mice and human CMD patients possibly results from different mechanisms. The F376del CMD mutation integrates into the membrane contrary to the lack of generation of ANK protein in ank/ank or ank-null mice and stimulates osteoblastogenic differentiation despite its total loss of PP i transport activity, suggesting that CMD mutant ANK and wildtype ANK may interact with other intracellular proteins and that these interactions affect signaling pathways and other cellular functions important to the regulation of osteoblast and osteoclast differentiation. The notion that wild-type or mutant forms of ANK may interact with other proteins is supported by a recent study showing the interaction of wild-type ANK with the Na þ -P i cotransporter Pit-1. (46) In addition, previous findings showed that the proline-to-leucine mutation at position 5 (P5L) in ANK cannot stimulate hypertrophic growth plate chondrocyte differentiation as wild-type ANK despite the increased PP i transport activity of the P5L mutation compared with wild-type ANK. (47) In conclusion, our findings provide evidence that ANK plays an important role in osteoblastogenic and osteoclastogenic differentiation and that the lack of ANK function results in delayed osteoblastogenic and osteoclastogenic differentiation. In addition, our findings reveal that ANK regulates osteoblastogenic differentiation by controlling extracellular PP i /P i homeostasis and that PP i directly and P i as a result of PP i hydrolysis are involved in ANK-mediated regulation of osteoblastogenesis. It is possible that ANK-mediated control of extracellular PP i /P i homeostasis also controls osteoclast differentiation because previous studies have shown that extracellular P i plays a role in osteoclastogenesis. (39, 48) Our findings, however, also suggest that ANK and/or CMD mutant forms of ANK may use interactions with other proteins to regulate osteoblast and osteoclast differentiation. Finally, our findings suggest that ANK regulates bone formation not only during development but also during bone remodeling and therefore may be a novel candidate gene that is important in the development of osteoporosis, a disease characterized by loss of bone mass and strength and often resulting in bone fracture from even minor trauma. Future studies are needed to establish the signaling pathways used by ANK to control these important events during bone remodeling.
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